ORGANOGENESIS HOLDINGS INC. - CLASS A

CORRECTING and REPLACING – Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results

10 May 2021 17:12:56 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results

10 May 2021 16:05:01 By Nasdaq GlobeNewswire

Organogenesis Appoints Jon Giacomin to Board of Directors

10 May 2021 07:30:00 By Nasdaq GlobeNewswire

Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring | WHS 2021 Virtual Meeting

06 May 2021 17:23:02 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2021 Financial Results on May 10, 2021

12 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2020 Financial Results; Introduces Fiscal Year 2021 Guidance

16 Mar 2021 16:05:01 By Nasdaq GlobeNewswire

Organogenesis Appoints David C. Francisco as Chief Financial Officer

16 Feb 2021 07:00:01 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February and March

09 Feb 2021 16:05:01 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 16, 2021

08 Feb 2021 16:05:00 By Nasdaq GlobeNewswire

Organogenesis Enrolls First Patient in Pivotal Phase 3 Clinical Trial of RMAT-Designated ReNu® for Knee Osteoarthritis

14 Jan 2021 07:00:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. Reports Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020

13 Jan 2021 16:05:00 By Nasdaq GlobeNewswire

Organogenesis ReNu® Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Osteoarthritis of the Knee

11 Jan 2021 09:01:30 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Participate in the ICR Conference 2021

05 Jan 2021 16:05:00 By Nasdaq GlobeNewswire